AbbVie Maintains Xeljanz Safety Concerns Don’t Spill Over To Rinvoq
Executive Summary
Responding to Pfizer post-marketing data indicating risk for CV events or cancer in patients taking Xeljanz, AbbVie tells Q4 earnings call that a more selective JAK inhibitor like Rinvoq will offer better safety.
You may also be interested in...
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of US Biosimilars
A year out from US competition to top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain for the originator until 2024.
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of Biosimilars
A year out from the US patent expiration for top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain until 2024.
AbbVie Says Rinvoq Holding Up, Humira Erosion Will Continue Into 2024
Physician response to FDA’s label change limiting Rinvoq to second-line-plus has been as expected, AbbVie said. Humira passed the $20bn sales threshold in 2021, but US biosimilar competition is one year away.